Maxim Maintains Buy On StemCells Following Third Quarter Update
Maxim Group analyst Jason Kolbert maintained a Buy rating on StemCells (NASDAQ:STEM) with a price target of $5.00, as the company reported results for 3Q14 with a loss of $2.8 million or $(0.04) per share, with cash at the end of the quarter of $32.2 million.
Kolbert noted, “Our thesis remains intact. We see multiple trials are now ongoing, and we agree with management that we are approaching an inflection period with the company, driven by proof-of concept data that should emerge over the next two years.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 4.5% and a 42.1% success rate. Kolbert has a -22.1% average return when recommending STEM, and is ranked #805 out of 3365 analysts.